Famciclovir Tablets (Famciclovir)

Adult dose

1. Treatment of herpes zoster infection Adults: Administer famciclovir 250 mg orally per dose 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of first-episode genital herpes infection Adults: Administer this medicine 250 mg orally per dose 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer this medicine 125 mg orally per dose 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this medicine 250 mg orally per dose 2 times daily. Periodically discontinue treatment every 6～12 months to assess any changes in the natural course of the disease. 5. Patients with renal impairment: Because the creatinine clearance of this medicine is reduced in patients with renal impairment, dose adjustment should be undertaken with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and first-episode genital herpes infections: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg per dose once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg per dose 2 times daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, administration every 48 hours is preferable, taking the dialysis interval into account. Since 4 hours of hemodialysis reduces the plasma concentration of this medicine by approximately 75%, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This medication should not be used in patients who have had a hypersensitivity reaction to this drug, its components, or the active ingredient penciclovir. Additionally, since this medication contains lactose, it should not be administered to patients with genetic issues such as lactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients with renal impairment should use this medication cautiously, and dosage adjustment may be necessary. While taking this medication, various side effects such as headache, nausea, dizziness, drowsiness, skin rash, and liver function abnormalities may occur, so any unusual symptoms should prompt immediate consultation with healthcare professionals. This medication does not completely cure genital herpes; therefore, it is important to avoid sexual contact and maintain safe sexual practices if symptoms persist during treatment. If dizziness, drowsiness, or confusion occurs while taking this medication, one should refrain from driving or operating machinery. In patients with mild liver impairment, no special dosage adjustments are typically required, but caution is advised in patients with severe liver impairment, as effectiveness may decrease. This medication may interact with other drugs, so it is essential to consult healthcare professionals, especially when taken in conjunction with probenecid or lamotrigine, for possible dosage adjustment or monitoring of side effects. Women who are pregnant or breastfeeding should carefully consider the benefits and risks of using this medication, and while there are no specific restrictions for women of childbearing age, consulting with healthcare professionals is advisable. Use in children under 18 years of age is not recommended as safety and effectiveness have not been established. In the elderly, dosage adjustment is generally not needed, but dosage may need to be adjusted if renal function declines. In case of overdose, immediate medical attention should be sought, and hemodialysis can help reduce drug concentration. This medication should be stored in a dry place below 30 degrees Celsius and kept out of reach of children. Transferring it to another container may adversely affect quality, so it should be avoided.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is advisable to keep it in a cool, dry place below 30 degrees Celsius.

Appearance

White round film-coated tablets

Package unit

Domestic: 21 tablets (7 tablets/PTP x 3), Export: 21 tablets (7 tablets/PTP x 3)